Management of Raynaud's Phenomenon in Patients Intolerant to Nifedipine

Introduction to Alternative Therapies

The European League Against Rheumatism recommends that for patients with Raynaud's phenomenon who cannot tolerate nifedipine due to hypotension, phosphodiesterase-5 (PDE5) inhibitors should be used as the next-line therapy, with intravenous prostacyclin analogues reserved for severe or refractory cases 1, 2

Other dihydropyridine calcium channel blockers, such as amlodipine or felodipine, can be considered if nifedipine specifically causes intolerable hypotension, as they may have different hemodynamic profiles while maintaining efficacy for Raynaud's phenomenon 1, 3

PDE5 inhibitors (sildenafil, tadalafil, or vardenafil) are the preferred alternative when calcium channel blockers cannot be tolerated, according to the American College of Rheumatology 4, 2
Meta-analysis of 6 RCTs including 236 patients with connective tissue disease-related Raynaud's showed PDE5 inhibitors significantly improve daily attack frequency (mean difference: -0.49 attacks), attack severity (mean difference: -0.46), and daily attack duration (mean difference: -14.62 minutes) 4
Common side effects of PDE5 inhibitors include vasomotor reactions, myalgias, dyspepsia, nasal stuffiness, and visual abnormalities—but notably less hypotension than calcium channel blockers 4

For severe or refractory Raynaud's phenomenon, intravenous iloprost should be considered, as recommended by the European Society of Cardiology, with significant reductions in the number of attacks and improvements in healing of digital ulcers 4, 2
Adverse effects of intravenous iloprost include tachycardia, hypotension, jaw pain, gastrointestinal symptoms, and headache—hypotension remains a concern 2

Topical nitrates (nitroglycerin or glyceryl trinitrate) may show clinical and blood flow improvement in meta-analysis of ~200 patients, but headache is a limiting side effect and they are contraindicated with concurrent PDE5 inhibitor use, as per the American Heart Association 2

The American College of Cardiology advises to never use sumatriptan or other vasoconstrictive agents in patients with Raynaud's phenomenon due to their vasoconstrictive mechanism, which directly opposes the vasodilatory treatment paradigm and risks serious vascular events including digital ischemia 5